Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Triamterene is a potassium-sparing diuretic used to treat edema (fluid retention) associated with conditions such as congestive heart failure, liver cirrhosis, nephrotic syndrome, and secondary hyperaldosteronism. It is also used alone or in combination with other medications to manage hypertension (high blood pressure). Triamterene works by directly inhibiting the epithelial sodium channel (ENaC) in the distal renal tubule and collecting duct of the nephron. This action blocks sodium reabsorption while reducing potassium excretion, thereby promoting diuresis without significant loss of potassium. Unlike spironolactone, which antagonizes aldosterone receptors, triamterene acts directly on ENaC channels. The drug is often combined with thiazide diuretics to enhance efficacy and maintain potassium balance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on triamterene.